secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001654954-24-014289
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata nears completion of DMT310 Phase 3 enrollment; Q3 2024 cash at $6.1M
----------------------------------------------------------------------------

- Enrollment in DMT310 Phase 3 STAR-1 acne trial expected to complete by end of 2024; topline results Q1 2025.
- Cash and equivalents of $6.1M at Sep 30, 2024; expected to fund operations into Q2 2025.
- Raised $7.8M in gross proceeds during 2024, including $5.1M in Q3 2024.
- R&D expenses $2.4M in Q3 2024, up from $0.9M due to STAR-1 clinical trial costs.
- G&A expenses $0.8M in Q3 2024, down from $0.9M in Q3 2023 on lower insurance costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424014289/0001654954-24-014289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424014289/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-014289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer